Table 1. Clinicopathological features of the patients.
| Variables | TC (n=95) | AC (n=33) | All (n=128) |
|---|---|---|---|
| Sex, n [%] | |||
| Male | 29 [31] | 17 [52] | 46 [36] |
| Female | 66 [69] | 16 [48] | 82 [64] |
| Age (years) | |||
| Mean | 52 | 55 | 53 |
| Median | 53 | 55 | 55 |
| Range | 19–84 | 23–77 | 19–84 |
| Tumor size (cm), n [%] | |||
| ≤1 | 29 [31] | 10 [30] | 39 [31] |
| 1.1–2.9 | 56 [59] | 15 [46] | 71 [55] |
| ≥3 | 10 [10] | 8 [24] | 18 [14] |
| Nodal involvement at diagnosis, n [%] | |||
| Yes | 3 [3] | 6 [18] | 9 [7] |
| No | 67 [71] | 24 [73] | 91 [71] |
| Not examined | 25 [26] | 3 [9] | 28 [22] |
| Distant metastasis, n [%] | |||
| At diagnosis | 0 [0] | 2 [6] | 2 [2] |
| During follow-up | 6 [6] | 5 [15] | 11 [9] |
| Surgical procedure, n [%] | |||
| Lobectomy | 40 [49] | 17 [55] | 57 [51] |
| Sleeve resection | 14 [17] | 8 [26] | 22 [19] |
| Segmentectomy | 14 [17] | 1 [3] | 15 [13] |
| Wedge resection | 9 [11] | 1 [3] | 10 [9] |
| Bilobectomy | 1 [1] | 2 [6] | 3 [3] |
| Enucleation | 3 [4] | 0 [0] | 3 [3] |
| Pneumoectomy | 0 [0] | 2 [6] | 2 [2] |
| Not available | 14 | 2 | 16 |
| Neoadjuvant treatment, n | |||
| Chemotherapy | 0 | 0 | 0 |
| Radiotherapy | 0 | 1 | 1 |
| Both | 0 | 1 | 1 |
| Adjuvant treatment†, n | |||
| Chemo/radio therapy only | 1 | 3 | 4 |
| SSAs only | 1 | 1 | 2 |
| SSAs + chemotherapy | 0 | 1 | 1 |
| SSAs + PRRT | 1 | 1 | 2 |
| SSAs + PRRT + chemo/radiotherapy | 1 | 1 | 2 |
| Ki-67 labeling index, n [%] | |||
| <1% | 43 [46] | 10 [30] | 53 [42] |
| 1–2% | 43 [46] | 18 [54] | 61 [48] |
| >2% | 7 [8] | 5 [16] | 12 [10] |
| Not available | 2 | 2 | |
†, adjuvant treatments were given only for metastatic disease. TC, typical carcinoid tumor; AC, atypical carcinoid tumor; SSA, somatostatin analog; PRRT, peptide receptor radionuclide therapy.